Aug 19, 2022 / 12:00PM GMT
Operator
Good morning, and welcome to Axsome Therapeutics conference call. (Operator Instructions)
With that, I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Mark, please go ahead.
Mark L. Jacobson - Axsome Therapeutics, Inc. - COO & Secretary
Thank you, operator. Good morning, and thank you all for joining us on today's conference call. This morning, we issued a press release announcing the approval of AUVELITY for the treatment of major depressive disorder. The release crossed the wire a short time ago and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development plans,
Axsome Therapeutics Inc Auvelity FDA Approval Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot